Quantitative proteomic analysis reveals maturation as a mechanism underlying glucocorticoid resistance in B lineage ALL and re-sensitization by JNK inhibition

Br J Haematol. 2015 Nov;171(4):595-605. doi: 10.1111/bjh.13647. Epub 2015 Aug 27.

Abstract

Glucocorticoid (GC) resistance is a continuing clinical problem in childhood acute lymphoblastic leukaemia (ALL) but the underlying mechanisms remain unclear. A proteomic approach was used to compare profiles of the B-lineage ALL GC-sensitive cell line, PreB 697, and its GC-resistant sub-line, R3F9, pre- and post-dexamethasone exposure. PAX5, a transcription factor critical to B-cell development was differentially regulated in the PreB 697 compared to the R3F9 cell line in response to GC. PAX5 basal protein expression was less in R3F9 compared to its GC-sensitive parent and confirmed to be lower in other GC-resistant sub-lines of Pre B 697 and was associated with a decreased expression of the PAX5 transcriptional target, CD19. Gene set enrichment analysis showed that increasing GC-resistance was associated with differentiation from preB-II to an immature B-lymphocyte stage. GC-resistant sub-lines were shown to have higher levels of phosphorylated JNK compared to the parent line and JNK inhibition caused re-sensitization to GC. Exploiting this maturation may be key to overcoming GC resistance and targeting signalling pathways linked to the maturation state, such as JNK, may be a novel approach.

Keywords: B cell differentiation; JNK signalling; childhood acute lymphoblastic leukaemia; glucocorticoid resistance; iTRAQ proteomics.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • B-Lymphocytes / drug effects*
  • B-Lymphocytes / pathology
  • Cell Differentiation / drug effects
  • Cell Line, Tumor
  • Dexamethasone / pharmacology*
  • Drug Resistance, Neoplasm / drug effects*
  • Drug Resistance, Neoplasm / physiology
  • Exons / genetics
  • Gene Expression Regulation, Leukemic / drug effects
  • Humans
  • MAP Kinase Kinase 4 / antagonists & inhibitors*
  • MAP Kinase Signaling System / drug effects*
  • Multiplex Polymerase Chain Reaction
  • Mutation
  • Neoplasm Proteins / antagonists & inhibitors
  • Neoplasm Proteins / biosynthesis*
  • Neoplasm Proteins / genetics
  • PAX5 Transcription Factor / genetics
  • PAX5 Transcription Factor / physiology
  • Phosphorylation / drug effects
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / enzymology
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology*
  • Protein Kinase Inhibitors / pharmacology*
  • Protein Processing, Post-Translational / drug effects
  • Proteomics / methods*
  • Real-Time Polymerase Chain Reaction
  • Tandem Mass Spectrometry

Substances

  • Antineoplastic Agents
  • Neoplasm Proteins
  • PAX5 Transcription Factor
  • PAX5 protein, human
  • Protein Kinase Inhibitors
  • Dexamethasone
  • MAP Kinase Kinase 4